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Abstract A new scorpion toxin (3751.8 Da) was isolated from
the Buthus martensi venom, sequenced and chemically synthe-
sized (sBmTX3). The A-type current of striatum neurons in
culture completely disappeared when 1 WM sBmTX3 was applied
(Kd = 54 nM), whereas the sustained K+ current was unaffected.
125I-sBmTX3 specifically bound to rat brain synaptosomes
(maximum binding = 14 fmol mg^1 of protein, Kd = 0.21 nM).
A panel of toxins yet described as specific ligands for K+
channels were unable to compete with 125I-sBmTX3. A high
density of 125I-sBmTX3 binding sites was found in the striatum,
hippocampus, superior colliculus, and cerebellum in the adult rat
brain. ß 2001 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
K channels play crucial roles in many di¡erent cellular
functions including cell excitability, neurotransmitter release,
hormonal secretion, signal transduction, cell volume regula-
tion, and neuronal integration [1]. Fast transient K channels
(transient A) are of particular interest because they regulate
¢ring frequency, spike initiation and waveform of action po-
tential [1]. Physiological studies show that A-type currents
exhibit a wide range of biophysical and pharmacological
properties, according to their cellular functions, as well as a
molecular heterogeneity. Few speci¢c blockers acting on A-type
K channels have been identi¢ed. They are heteropodatoxins
(HpTX) and phrixotoxin (PaTX), from the spiders Heterapo-
da venatoria [2] and Phrixotrichus auratus [3], which block the
Kv4.2/Kv4.3 channels; BDS I and II from the sea-anemone
Anemonia sulcata, which block Kv3.4 [4]. In addition to being
useful tools to characterize, classify and study the physiolog-
ical roles of K channels, analysis of these toxins provides a
structural basis for the potential design of new pharma-
ceutical agents [4]. Thus, the characterization of new toxins,
inhibitor of A-type currents, is expected to be informative
about the role of sustaining channels in neural and cardiac
tissue.
Recently, Aa1, a new blocker of fast K currents from
cerebellum granular cells was isolated from the venom of
the scorpion Androctonus australis [5]. Here, we describe the
chemistry, the pharmacology and the rat brain binding sites
distribution of a Buthus martensi Karch scorpion toxin,
BmTX3, which blocks an A-type current in neurons of stria-
tum cells in culture.
2. Materials and methods
2.1. Venoms and toxins
The B. martensi venom was collected as described [6]. Kaliotoxin
(KTX) and P05 from Androctonus mauretanicus were synthesized as
described [7,8]. Charybdotoxin (ChTX), iberiotoxin (IbTX), and mast
cell degranulating peptide (MCD peptide) were from Bachem; apamin
was from Sigma; K-DTX was puri¢ed from Dendroaspis angusticep
[9]. BDS-I and BDS-II from A. sulcata and recombinant noxiustoxin
(rNTX) from Centruroides noxius were from Alomone Labs. HpTX1
from H. venatoria was from NPS Pharmaceuticals Inc.
2.2. Puri¢cation, amino acid composition and sequence determination of
BmTX3
Puri¢cation conditions are described in ¢gure legends. Amino acid
compositions were determined as described [6]. 3 nmol of BmTX3
were S-carboxymethylated. Treatment with pyroglutamate aminopep-
tidase (Boehringer, Germany) unblocked the N-terminal glutamate
residue before sequencing [10,11]. Toxicity in vivo was tested on 20
g male C57 Bl/6 mice by i.c.v. injection as described [12].
2.3. Chemical synthesis of BmTX3
Solid phase synthesis of BmTX3 was performed using the FastMoc
program, as described [13]. The identity of synthetic and natural
products was veri¢ed by amino acid analysis after acid hydrolysis,
by a C18 RP HPLC co-injection experiment using a gradient from
5% to 45% of 0.1% tri£uoroacetic acid in acetonitrile in 40 min with
initial isocratic conditions for 3 min (the synthetic and natural prod-
ucts coeluted at 27.6 min) and using MALDI-TOF mass spectrome-
try.
2.4. Patch recording of striatal neurons in culture
For primary culture of striatal neurons, striata were dissected from
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18 day old Sprague^Dawley rat embryos and cultured according to
Ref. [14]. Neurons were studied using whole cell patch clamp tech-
nique. The bath solution contained (in mM): 140 NaCl, 2 KCl, 0.8
MgCl2, 1.8 CaCl2, 0.4 Na2HPO4 and 10 HEPES, pH 7.3. sBmTX3
was applied under pressure with a broken pipette. Experiments were
carried out at room temperature (20^24‡C). Patch pipettes were ¢lled
with (in mM): 120 KCl, 10 NaCl, 2 MgCl2, 0.56 CaCl2, 1 EGTA and
10 HEPES, pH 7.4. Capacity transient compensation was routinely
performed in the cell-attached mode before patch membrane rupture.
In the whole cell voltage clamp con¢guration, capacitive transients
and leakage currents were subtracted using a factored hyperpolarizing
pulse, without additional transient or series resistance compensation.
2.5. Iodination of sBmTX3 and pharmacological tests
sBmTX3 (0.5 nmol) was iodinated using lactoperoxidase [15] and
the free iodide eliminated as described [12]. Speci¢c radioactivities of
2000 cpm/fmol were routinely obtained. Analysis of the mono or di-
iodo derivatives was followed by MALDI-TOF mass spectrometry.
Rat brain synaptosomal fraction P2 (90 Wg/assay in a total volume
of 200 Wl) was used for binding assays in binding bu¡er (20 mM Tris^
HCl pH 7.4, 50 mM NaCl, 0.1% BSA). Non-speci¢c binding was
determined throughout in the presence of 0.1 WM unlabeled sBmTX3.
Incubation was 1 h at 25‡C. Reaction was stopped by dilution, adding
4 ml of wash bu¡er (20 mM Tris^HCl, pH 7.4, 150 mM NaCl, 1%
BSA) and the solution was immediately ¢ltered through a GF/C ¢lter
soaked in 0.1% polyethylenimine. Filters were washed twice and the
¢lter-retained radioactivity was determined by Q-counting. Each point
was made in triplicate. All the data were subjected to non-linear
regression analysis using PRISM (GraphPad) and assuming the pres-
ence of a single class of binding sites.
Fig. 1. Puri¢cation and electrophysiological testing of BmTX3. a: Reverse-phase C18 HPLC pro¢le of the soluble venom (300 mg) from B.
martensi scorpion. A linear gradient of 0.1% TFA^acetonitrile was applied on a semipreparative column Shiseido Capcell pak (25U1 cm, 120
Aî , 5 Wm) from 0 to 45% over 120 min at a £ow rate of 3 ml min31. The component used for subsequent puri¢cation numbered 7 is in black.
b: Puri¢cation of fraction 7 by cation exchange chromatography on a sulfopropyl column. 1/6 of fraction 7 was loaded on a cation exchange
Tosoh, TSK-gel, sulfopropyl SP-5PW, 0.6U7 cm HPLC column in 10 mM sodium phosphate. A linear gradient from 0 to 800 mM NaCl, pH
6.8, was applied over 80 min at a £ow rate of 0.5 ml min31. BmTX3 eluted by 490 mM NaCl. c: sBmTX3 blocks the A-current of the striatal
neurons in culture. Total currents elicited from a Vh of 3100 mV in control conditions and after application (17 min) of 1 WM of sBmTX3.
Depolarization between 360 mV and 0 mV with steps of 10 mV. Currents recorded in the presence of sBmTX3 were compared to currents re-
corded from a Vh of 370 mV, a holding potential that inactivates the A-type current.
FEBS 25033 6-7-01
H. Vacher et al./FEBS Letters 501 (2001) 31^3632
2.6. Autoradiographic procedures
Anaesthetized adult male Sprague^Dawley rats (150^200 g) were
killed by decapitation, and their brains were removed and frozen.
Sagittal cryostat sections (15 Wm) were collected and stored at
360‡C until use. The brain sections were incubated with 0.5 nM
125I-sBmTX3 at 4‡C in binding bu¡er. The non-speci¢c binding com-
ponent was measured by addition of 0.1 WM sBmTX3, 15 min before
the addition of 125I-sBmTX3. After a 60 min incubation, the sections
were rinsed four times (with each wash lasting 30 s) in wash bu¡er
and then rinsed once (3 s) in the same bu¡er containing 0.1% BSA.
The dried slices were exposed to Kodak Biomax MR ¢lms that were
processed after a 15 day exposure. Rat brain regions were identi¢ed
according to the rat brain atlas [16].
3. Results
3.1. Puri¢cation, amino acid sequence determination, and
chemical synthesis of BmTX3
The venom of the Chinese scorpion B. martensi was
screened using HPLC, MALDI-TOF mass spectrometry and
toxicological analysis. The fraction 7 (Fig. 1a) contained low
molecular weight toxins, one of which (BmTX3) had a mass
of 3751.8 Da (Fig. 1b). When injected in mice (8 Wg i.c.v.), it
caused epileptiform behavior. Its amino acid composition
analysis gave the following ratios: 1.9 Asx (2); 3.0 Glx (3);
1.9 Ser (2) ; 5.3 Gly (5); 1.1 Thr (1); 4.1 Ala (4); 1.1 Pro (1);
2.1 Arg (2); 0.9 Tyr (1) ; 4.7 Val (5); 2.0 Ile (2); 3.0 Lys (3). It
accounted for 0.06% of the dry mass of the venom. No PTH-
amino acid was detected at the ¢rst step of the sequencing
process of BmTX3, suggesting that it was blocked at its N-ter-
minal extremity. The molecular mass of the native peptide
was nearly 16 Da lower than that deduced from amino acid
composition, including six putative cysteine residues (3768.3
Da). This di¡erence was in accordance with the presence of a
pyroglutamic acid residue at the N-terminus, as it is the case
for ChTX. After treatment by pyroglutaminase, S-carboxyme-
thylated BmTX3 was successfully sequenced. Thus, BmTX3
was composed of a single chain of 37 amino acid residues,
most probably reticulated by three disul¢de bridges since six
carboxymethyl-cysteines were detected (Fig. 2). BmTX3 had
89% sequence homology with the recently described toxin Aa1
Fig. 2. Amino acid sequence of BmTX3. The sequence of BmTX3 is
aligned with Aa 1 from A. australis [5] and ChTX from Leiurus
quinquestriatus hebraeus [10] according to their half-cystine and gaps
were introduced to enhance sequence similarities. Identities among
the three sequences are boxed. Di¡erences between BmTX3 and Aa
1 are in gray. Z indicates pyroglutamate. The arrows are L-strands
and the helix is K-helix as observed for ChTX.
Fig. 3. Characterization of 125I-sBmTX3 binding to rat brain P2. a: Competitive binding of 400 pM 125I-sBmTX3 with native BmTX3 (R) or
sBmTX3 (F). b: Equilibrium binding of 125I-sBmTX3 (10^380 pM) to rat brain P2 : (F) total binding; non-speci¢c binding (R); speci¢c bind-
ing (S). Inset: Scatchard plot of the data. c: Dissociation was measured after incubation (1 h) of 400 pM 125I-sBmTX3. d: Association of
125I-sBmTX3 was measured as illustrated for 400 pM. kobs values were determined for speci¢c binding at 400, 200 and 100 pM (see inset).
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from A. australis (K-KTX4.4) [5]. The N-terminal pyrogluta-
mic acid and Tyr36 had already been found in the ChTX
family (K-KTX1.1). The highly conserved region involved in
channel recognition [7,17^19], i.e. the L-sheet 26^32, contained
some important di¡erences to other scorpion toxins blocking
K channels: Ile29 instead of Met and Arg32 instead of Lys.
BmTX3 was chemically synthesized on solid phase. Yields
of assembly and cleavage were 85% and 60%, respectively.
The yield of the oxidation step was 1.6% for synthetic toxin
(sBmTX3). sBmTX3 showed the same amino acid composi-
tion as the natural toxin, the same molecular mass (3751.6 vs
3751.8 Da), and coeluted with the natural toxin as a single
peak in HPLC. Therefore, synthetic sBmTX3 was used for
further biological characterization.
3.2. Whole cell patch recording of striatal neurons in culture
The current blocked by sBmTX3 was characterized by per-
forming whole cell patch recording using striatal neurons in
primary cell culture. Fig. 1c shows the inward and the out-
ward currents recorded in control conditions from two hold-
ing potentials (Vh) of 3100 and 370 mV. From a Vh of 3100
mV both the A-type current and the sustained K current
were activated. From a Vh of 370 mV the A-type current
was inactivated and the sustained K current slightly inacti-
vated (almost una¡ected). In the presence of sBmTX3 (1 WM)
the A-type current completely disappeared whereas the sus-
tained K current remained una¡ected. Dose^response experi-
ments indicated a Kd of 54 nM (not shown).
3.3. Radioiodination of sBmTX3 and determination of the
binding parameters
The single tyrosine residue of BmTX3 at the penultimate
position allowed its radioiodination. MALDI-TOF mass spec-
trometry analysis of the product con¢rmed that only a mono-
iodo derivative was obtained (3876.3 Da).
125I-sBmTX3 binding to rat brain P2 was ¢rst evaluated in
competition experiments using native BmTX3 and sBmTX3
which behaved identically (Fig. 3a). Both completely displaced
125I-sBmTX3 from its binding site with IC50 values in the 0.22
nM range. Saturation experiments showed that 125I-sBmTX3
associated in a concentration dependent manner (Fig. 3b).
The speci¢c binding (de¢ned as the di¡erence between the
total 125I-sBmTX3 binding and the binding in the presence
of 100 nM unlabeled sBmTX3) was a saturable function of
125I-sBmTX3 concentrations giving a Kd of 0.21 þ 0.05 nM
and a Bmax of 14 fmol mg31 of protein (n = 3). The non-spe-
ci¢c binding ranged from 35 to 45% of the total binding.
Adding an excess (100 nM) of unlabeled sBmTX3 initiated
dissociation of prebound 125I-sBmTX3 from its site (Fig.
3c). The ¢rst order dissociation rate constant koff was
6.0U1034 þ 2.6U1034 s31 (n = 2) giving a t1=2 of 17 min. In-
cubation of rat brain P2 with various concentrations of 125I-
sBmTX3 (0.4 nM, 0.2 nM and 0.1 nM) revealed a concentra-
tion and time dependent association of the toxin (Fig. 3d).
The second order association rate constant kon was
6.0U106 þ 0.2U106 M31 s31 (n = 2). The Kd value calculated
from these kinetic constants was koff /kon = 0.1 nM, in good
agreement with that determined under equilibrium binding
conditions.
3.4. Competition experiments with other K+ channel blockers
The Kv1. family blockers KTX, rNTX, ChTX (also blocker
of the BKCa channel), MCD peptide and K-DTX (all up to
0.1 WM) did not compete with 125I-sBmTX3. BDS-I and BDS-
II which are blockers of Kv3.4 and HpTX1, a blocker of the
Kv4.2/Kv4.3, were also unable to compete with 125I-sBmTX3
(all up to 0.1 WM). Only apamin (a blocker of the SKCa
channels) slightly displaced 125I-sBmTX3 from its binding
site but at doses s 1 WM. 125I-sBmTX3 binding was inhibited
by 15 mM TEA and 18 mM 4-AP. The inhibition of K
channels by TEA and 4-AP has been well documented [20,21].
3.5. Distribution of sBmTX3 binding sites in adult rat brain
The distribution of sBmTX3 binding sites in the rat brain
was heterogeneous and the high grain levels predominated in
very few structures (Fig. 4a,b). Non-speci¢c binding was uni-
form in the di¡erent brain regions and no variation was de-
tectable between the gray and the white matter (Fig. 4c). In
the telencephalon, very high densities of sBmTX3 binding
sites were present, in the caudate putamen and the accumbens
nucleus whereas the neocortex, the globus pallidum, and the
septum contained low to intermediate levels of binding sites.
In the hippocampus, the sBmTX3 sites were not homoge-
Fig. 4. Distribution of 125I-BmTX3 binding sites in parasagittal sec-
tions of rat brain. In the autoradiograms, the dark areas indicate
the high grain density, i.e. high binding site density. The non-specif-
ic binding (NSB) was homogeneous throughout the brain. Bar =
2 mm. Abbreviations: Acb, accumbens nucleus; AV, anteroventral
thalamic nucleus; CA1, ¢eld 1 of Ammon’s horn; CPu, caudate pu-
tamen; Cx, neocortex; DG, dentate gyrus; GP, globus pallidus; Gr,
granular layer of the cerebellum; LS, lateral septum; OB, olfactory
bulb; Pn, pons; Sp5, spinal trigeminal nucleus; SuG, superior colli-
culus.
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neously distributed. The strati oriens and radiatum of the
CA1 and CA3 ¢eld were more heavily labeled with high den-
sities than the stratum lacunosum moleculare. The molecular
layer of the dentate gyrus also presented high densities of
sBmTX3 sites. In the subiculum, the density of sites was
low. There were few sites in the rhinenchephalon, however
the anterior olfactory nucleus showed an intermediate label-
ing. In the diencephalon, an intermediate level of sBmTX3
binding sites was observed in the thalamic nuclei particularly
in the anterior nucleus whereas the speci¢c binding, in the
other regions, was very low in particular in the hypothalamus.
In the mesencephalon, the density of sBmTX3 sites was ho-
mogeneous and low except in the superior colliculus where
labeling was dense. The metencephalon was weakly labeled.
In the medulla, only the pontine nuclei presented an inter-
mediate level of sites whereas the other structures contained
low levels. The cerebellum showed a heterogeneous distribu-
tion of the sBmTX3 binding sites with a high density in the
granular layer, an intermediate density in the molecular layer,
and no labeling in the ¢ber tracts. At histological resolution,
labeling in the Purkinje cell layer could not be excluded. In
the white matter, there was no detectable di¡erence between
the total and the non-speci¢c binding.
4. Discussion
4.1. BmTX3 and Aa1 de¢ne a new group of transient K+
current blocker
The chemical and electrophysiological data concerning
sBmTX3 are in agreement with the results obtained with
Aa1, which blocks transient K currents in cerebellum gran-
ular cells with a Kd around 150 nM [5]. At the amino acid
sequence level, BmTX3, like Aa 1, contains the conserved
structural signature of scorpion toxins, i.e. an K-helix linked
to an antiparallel L-sheet [22]. Interestingly, among the ¢ve
residues in the L-sheet generally involved in the binding of
KTX, AgTX2 and ChTX to the Shaker [17,18], Kv1.3 [7,19]
or BK channels [23], only three (Lys27, Asn30 and Tyr36) are
conserved in BmTX3. Nevertheless, BmTX3 retains the ability
to recognize some K channels.
Our electrophysiological experiments demonstrate that
sBmTX3 blocks a transient (A-type) K current expressed
in culture of striatal neurons. The striatum contains the cau-
date putamen, a region with a high density of 125I-sBmTX3
binding sites. These cultures contain numerous gabaergic neu-
rons and some cholinergic neurons [14]. To our knowledge, no
information is available concerning the nature of the subunits
constituting the transient K current in striatal gabaergic neu-
rons. However, striatal cholinergic interneurons contains
mRNAs for Kv1.4, Kv4.1 and Kv4.2 subunits [24].
4.2. BmTX3 de¢nes a new pharmacological binding site in rat
brain
125I-sBmTX3 is able to bind to speci¢c sites in rat brain
with a high a⁄nity. The same a⁄nities are obtained compar-
ing 125I-sBmTX3 binding and its competitive displacement by
BmTX3. This suggests that the iodination of BmTX3 does not
alter its activity. This result is signi¢cant as it was observed
for ChTX [25] and HgTX [26] that a bulky hydrophobic io-
dine at Tyr37 reduces the a⁄nity of the toxin. The density of
binding sites is lower (14 fmol mg31 of protein) than those of
125I-K-DTX (500^1100 fmol mg31 of protein) and 125I-MCD
peptide (160 fmol mg31 of protein) in identical rat brain syn-
aptosomal fractions [27]. It is di⁄cult to compare the number
of binding sites with those of other toxins (125I-ChTX or 125I-
HgTX), due to di¡erences in the characteristics of the rat
brain fractions used. However, this density of BmTX3 binding
sites is in the same range as those found for KTX (24 fmol
mg31 of protein) and for apamin (12.5 fmol mg31 of protein)
[28]. The sites detected were found to be highly speci¢c for
125I-sBmTX3. The binding was not inhibited by any of the K
channel peptidic blockers described.
4.3. BmTX3 de¢nes a new localization pattern in rat brain
Interestingly, the distribution of 125I-sBmTX3 binding sites
in adult rat brain is highly heterogeneous, suggesting a neuro-
nal labeling. However, the presence of 125I-sBmTX3 binding
sites in astrocytes cannot be excluded. This distribution with
high site densities in caudate putamen, is very di¡erent from
those of other peptidyl K channels toxins. Indeed, except in
hippocampus and cerebellum, DTX I, K-DTX and MCD pep-
tide binding sites are evenly distributed in the gray matter
[27,29,30]. 125I-KTX binding sites present a high density in
the neocortex, hypothalamus, stria terminalis, and parabra-
chial nucleus and a low level in caudate putamen [31]. For
MgTX, most of the brain regions contain a homogeneous
level of binding sites, with the exception of major ¢ber tracts
where the highest density is detected [32]. For apamin, high
binding is detected in hippocampus, but also in thalamus and
in septum where the levels of 125I-sBmTX3 binding sites are
low [33]. For ChTX, binding is moderate in caudate putamen
and in hippocampus but very high in hypothalamus and mes-
encephalum [34].
4.4. Concluding remarks
Autoradiographic experiments show that few structures in
the rat brain contain high densities of 125I-sBmTX3 binding
sites. The fact that the distribution of these sites is very di¡er-
ent from those of others toxins acting on K channels is
consistent with BmTX3 recognizing a channel type insensitive
to other known toxins. As a high density of 125I-sBmTX3
binding sites is found in the granular layer of the cerebellum,
we suppose that sBmTX3 and Aa1 recognize the same target
in rat brain. Accordingly, BmTX3 and Aa1 may constitute the
¢rst members of a new family of short chain scorpion toxins
active on transient K channels [35].
Acknowledgements: We thank Dr. P. Marchot for providing puri¢ed
K-DTX and G. Jacquet for helpful in patch-clamp experiments. This
study was supported by a grant from the DGA to H.V.
References
[1] Coetzee, W.A. et al. (1999) Ann. N. Y. Acad. Sci. 868, 233^285.
[2] Sanguinetti, M.C., Johnson, J.H., Hammerland, L.G., Kelbaugh,
P.R., Volkmann, R.A., Saccomano, N.A. and Mueller, A.L.
(1997) Mol. Pharmacol. 51, 491^498.
[3] Diochot, S., Drici, M.D., Moinier, D., Fink, M. and Lazdunski,
M. (1999) Br. J. Pharmacol. 126, 251^263.
[4] Diochot, S., Schweitz, H., Beress, L. and Lazdunski, M. (1998)
J. Biol. Chem. 273, 6744^6749.
[5] Pisciotta, M., Coronas, F.I., Bloch, C., Prestipino, G. and Pos-
sani, L.D. (2000) Biochim. Biophys. Acta 1468, 203^212.
[6] Romi-Lebrun, R., Martin-Eauclaire, M.F., Escoubas, P., Wu,
F.Q., Lebrun, B., Hisada, M. and Nakajima, T. (1997) Eur. J.
Biochem. 245, 457^464.
[7] Romi, R. et al. (1993) J. Biol. Chem. 268, 26302^26309.
FEBS 25033 6-7-01
H. Vacher et al./FEBS Letters 501 (2001) 31^36 35
[8] Sabatier, J.M., Zerrouk, H., Darbon, H., Mabrouk, K., Bensli-
mane, A., Rochat, H., Martin-Eauclaire, M.F. and Van
Rietschoten, J. (1993) Biochemistry 32, 2763^2770.
[9] Tricaud, N., Marchot, P. and Martin-Eauclaire, M.F. (2000)
Toxicon 38, 1749^1758.
[10] Gimenez-Gallego, G., Navia, M.A., Reuben, J.P., Katz, G.M.,
Kaczorowski, G.J. and Garcia, M.L. (1988) Proc. Natl. Acad.
Sci. USA 85, 3329^3333.
[11] Galvez, A., Gimenez-Gallego, G., Reuben, J.P., Roy-Contancin,
L., Feigenbaum, P., Kaczorowski, G.J. and Garcia, M.L. (1990)
J. Biol. Chem. 265, 11083^11090.
[12] Laraba-Djebari, F. et al. (1994) J. Biol. Chem. 269, 32835^32843.
[13] Romi-Lebrun, R. et al. (1997) Biochemistry 36, 13473^13482.
[14] Kowalski, C., Crest, M., Vuillet, J., Pin, T., Gola, M. and
Nieoullon, A. (1995) Neuroscience 64, 979^993.
[15] Rochat, H., tessier, M., Miranda, F. and Lissitzky, S. (1976) in:
Animal, Plant, and Microbial Toxins, Vol. 1, pp. 81^88, Plenum,
New York.
[16] Paxinos, G. and Watson, C. (1986), Academic Press, New York.
[17] Park, C.S. and Miller, C. (1992) Biochemistry 31, 7749^
77455.
[18] MacKinnon, R., Cohen, S.L., Kuo, A., Lee, A. and Chait, B.T.
(1998) Science 280, 106^109.
[19] Aiyar, J. et al. (1995) Neuron 15, 1169^1181.
[20] MacKinnon, R. and Yellen, G. (1990) Science 250, 276^279.
[21] Heginbotham, L., Abramson, T. and MacKinnon, R. (1992) Sci-
ence 258, 1152^1155.
[22] Bontems, F., Roumestand, C., Gilquin, B., Menez, A. and Toma,
F. (1991) Science 254, 1521^1523.
[23] Goldstein, S.A., Pheasant, D.J. and Miller, C. (1994) Neuron 12,
1377^1388.
[24] Song, W.J., Tkatch, T., Baranauskas, G., Ichinohe, N., Kitai,
S.T. and Surmeier, D.J. (1998) J. Neurosci. 18, 3124^3137.
[25] Tenenholz, T.C., Klenk, K.C., Matteson, D.R., Blaustein, M.P.
and Weber, D.J. (2000) Rev. Physiol. Biochem. Pharmacol. 140,
135^185.
[26] Koschak, A., Bugianesi, R.M., Mitterdorfer, J., Kaczorowski,
G.J., Garcia, M.L. and Knaus, H.G. (1998) J. Biol. Chem. 273,
2639^2644.
[27] Bidard, J.N., Mourre, C., Gandolfo, G., Schweitz, H., Widmann,
C., Gottesmann, C. and Lazdunski, M. (1989) Brain Res. 495,
45^57.
[28] Hugues, M., Duval, D., Kitabgi, P., Lazdunski, M. and Vincent,
J.P. (1982) J. Biol. Chem. 257, 2762^2769.
[29] Mourre, C., Bidard, J.N. and Lazdunski, M. (1988) Brain Res.
446, 106^112.
[30] Awan, K.A. and Dolly, J.O. (1991) Neuroscience 40, 29^39.
[31] Mourre, C., Chernova, M.N., Martin-Eauclaire, M.F., Bessone,
R., Jacquet, G., Gola, M., Alper, S.L. and Crest, M. (1999)
J. Pharmacol. Exp. Ther. 291, 943^952.
[32] Saria, A. et al. (1998) Eur. J. Pharmacol. 343, 193^200.
[33] Mourre, C., Hugues, M. and Lazdunski, M. (1986) Brain Res.
382, 239^249.
[34] Gehlert, D.R. and Gackenheimer, S.L. (1993) Neuroscience 52,
191^205.
[35] Tytgat, J., Chandy, K.G., Garcia, M.L., Gutman, G.A., Martin-
Eauclaire, M.F., van der Walt, J.J. and Possani, L.D. (1999)
Trends Pharmacol. Sci. 20, 444^447.
FEBS 25033 6-7-01
H. Vacher et al./FEBS Letters 501 (2001) 31^3636
